MS Therapy Trends Discussed in New FirstWord Study Published at

Share Article

New research study “Therapy Trends: Multiple Sclerosis” provided by FirstWord has been recently published by Market Publishers Ltd.

TD The Market Publishers Ltd

What are the key unmet needs? How will therapies be positioned against each other in the future of multiple sclerosis (MS) treatment? How will treatment developments play out in the near future? Is there potential for new players in the lucrative MS market? Where will Sanofi’s Lemtrada and Aubagio be positioned in treatment? How will the launch of biosimilars affect prescribing behavior? How will Novartis’s Gilenya be affected by recent safety concerns? Will the new John Cunningham Virus test encourage earlier adoption of Tysabri? The answers to all these critical questions and many more can be found in the research study.

New research study “Therapy Trends: Multiple Sclerosis” provided by FirstWord has been recently published by Market Publishers Ltd.

Report Details:

Title: Therapy Trends: Multiple Sclerosis
Published: April, 2012
Pages: 160
Price: US$ 4,995

The study delivers insight from the most influential multiple sclerosis (MS) key opinion leaders (KOLs) to uncover how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way multiple sclerosis is managed by neurologists in the future.

Key Benefits:

  •     unmet needs analysis enabling to identify opportunities and address the challenges facing disease management;
  •     strategic mapping of future treatment algorithms based on KOL insight;
  •     commercial and clinical analysis of pipeline therapies;
  •     in-depth, dynamic event impact assessments to evaluate current strategies and plans against new conditions;
  •     information of how to align investment and resource planning to future trends;
  •     overview of the story driving the trends.

Report Contents:

Executive Summary



Current Multiple Sclerosis Marketplace

Current treatment landscape
Multiple sclerosis market definition
Current market overview
Current therapies
Cross trial comparisons is not an ideal assessment
Gilenya (fingolimod; Novartis) trends
Gilenya has first oral to market advantage
Gilenya raises bar for pipeline therapies entering the market
Deaths mar Gilenya's side effect profile and positions drug as a second line
Vigilance program is cumbersome and likely to restrict access
Gilenya's high price will restrict use
Clinical trials in progressive multiple sclerosis ongoing
Tysabri (natalizumab; Biogen/Elan) trends
Tysabri is the most effective approved multiple sclerosis therapy
PML fears positions drug as second or later line
JCV test will promote use and allay fears
Progressive multiple sclerosis trials ongoing for Tysabri
Copaxone (glatiramer acetate; Teva) trends
Copaxone is the leading selling multiple sclerosis therapy
Teva fights generic Copaxone applications
Interferon betas (Avonex, Betaseron, Rebif, Extavia) trends
Interferons are the mainstay of multiple sclerosis treatment
Needles have evolved to avoid injection site reactions
Biosimilar guidelines in place for interferons
Current treatment algorithm
Multiple sclerosis unmet needs
Unmet need 1: Efficacy for progressive subtypes
Unmet need 2: Therapies offering better clinical profiles
Unmet need 3: Drugs to halt or repair neuronal damage
Unmet need 4: Improving multiple sclerosis induced cognition dysfunction
Unmet need 5: Need for improved adherence

Future Therapy Trends

BG-12 (dimethyl fumarate; Biogen) trends
Impressive efficacy and safety means BG-12 will become the leading multiple sclerosis pill
BG-12 will become a first-line therapy and a major threat to Gilenya
Unknown tolerability profile could prevent uptake
Delay in efficacy and compliance are other barriers for uptake
Aubagio (teriflunomide; Sanofi/Genzyme) trends
Aubagio exhibits strong safety profile but has moderate efficacy
Aubagio has potential positioning as a combination therapy
Pricing will determine Aubagio's success
Laquinimod (Teva) trends
Phase III efficacy data is disappointing and less than current therapies
Compelling disability data suggests role in neuroprotection
Safety data and mechanism suits role as an add-on therapy
Lemtrada (alemtuzumab; Genzyme/Sanofi) trends
Lemtrada is one of the most effective pipeline therapies
Safety concerns may hamper uptake and reserve Lemtrada as a last-line or induction therapy

More new research studies by the publisher can be found at FirstWord page.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler
Visit website